litlas
Log inCreate account

Gary K. Schwartz

Active 1978–2025

175
Papers
32,821
Citations
97
h-index
171
i10-index

Citations

Citations per year for Gary K. Schwartz1979: 1 citations1980: 2 citations1981: 1 citations1983: 2 citations1984: 1 citations1985: 3 citations1986: 3 citations1987: 5 citations1988: 1 citations1989: 5 citations1990: 4 citations1991: 5 citations1992: 8 citations1993: 7 citations1994: 11 citations1995: 7 citations1996: 10 citations1997: 14 citations1998: 24 citations1999: 31 citations2000: 47 citations2001: 52 citations2002: 71 citations2003: 92 citations2004: 51 citations2005: 99 citations2006: 93 citations2007: 103 citations2008: 145 citations2009: 160 citations2010: 214 citations2011: 227 citations2012: 198 citations2013: 274 citations2014: 276 citations2015: 297 citations2016: 432 citations2017: 562 citations2018: 442 citations2019: 1,205 citations2020: 1,361 citations2021: 1,367 citations2022: 1,050 citations2023: 870 citations2024: 1,249 citations2025: 708 citations2026: 20 citations1982: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,238 citing papers, 27.4% of this breakdownChina: 2,260 citing papers, 14.6% of this breakdownUnited Kingdom: 787 citing papers, 5.1% of this breakdownItaly: 704 citing papers, 4.6% of this breakdownGermany: 702 citing papers, 4.5% of this breakdownFrance: 598 citing papers, 3.9% of this breakdownJapan: 528 citing papers, 3.4% of this breakdownSpain: 430 citing papers, 2.8% of this breakdownCanada: 420 citing papers, 2.7% of this breakdownNetherlands: 419 citing papers, 2.7% of this breakdownAustralia: 410 citing papers, 2.7% of this breakdownIndia: 326 citing papers, 2.1% of this breakdown
0%27.4%Other 23.5%

Institutions

Fields

  • Medicine47.5%
  • Biochemistry, Genetics and Molecular Biology43.8%
  • Immunology and Microbiology3.2%
  • Engineering0.8%
  • Computer Science0.7%
  • Chemistry0.7%
  • Other3.3%

Topics

  • Extracellular vesicles in disease7.5%
  • MicroRNA in disease regulation5.1%
  • Sarcoma Diagnosis and Treatment3.2%
  • Cancer-related Molecular Pathways2.6%
  • RNA Interference and Gene Delivery2.3%
  • Cancer Immunotherapy and Biomarkers2.3%
  • Other77%

Coauthors

All papers

Open in search
  1. Tumour exosome integrins determine organotropic metastasis

    Authors: Ayuko Hoshino, Bruno Costa‐Silva, Tang‐Long Shen, Gonçalo Rodrigues, Ayako Hashimoto, Milica Tešić Mark, Henrik Molina, Shinji Kohsaka, Angela Di Giannatale, Sophia Ceder, Swarnima Singh, Caitlin Williams, Nadine Soplop, Kunihiro Uryu, Lindsay A. Pharmer, Tari A. King, Linda Bojmar, Alexander E. Davies, Yonathan Ararso, Tuo Zhang, Haiying Zhang, Jonathan M. Hernandez, Joshua M. Weiss, Vanessa D Dumont-Cole, Kimberly Kramer, Leonard H. Wexler, Aru Narendran, Gary K. Schwartz, John H. Healey, Per Sandström, Knut Jørgen Labori, Elin H. Kure, Paul M. Grandgenett, Michael A. Hollingsworth, Maria de Sousa, Sukhwinder Kaur, Maneesh Jain, Kavita Mallya, Surinder K. Batra, William R. Jarnagin, Mary S. Brady, Øystein Fodstad, Volkmar Muller, Klaus Pantel, Andy J. Minn, Mina J. Bissell, Benjamin A. García, Yibin Kang, Vinagolu K. Rajasekhar, Cyrus M. Ghajar, Irina Matei, Héctor Peinado, Jacqueline Bromberg, David Lyden - Nature 2015 cited by 5,185

  2. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

    Authors: Sandra P. D’Angelo, Dejka M. Araujo, Albiruni R. Abdul Razak, Mark Agulnik, Steven Attia, Jean‐Yves Blay, Irene Carrasco García, John A. Charlson, Edwin Choy, George D. Demetri, Mihaela Druta, Édouard Forcade, Kristen N. Ganjoo, John Glod, Vicki L. Keedy, Axel Le Cesne, David A. Liebner, Víctor Moreno, Seth M. Pollack, Scott M. Schuetze, Gary K. Schwartz, Sandra J. Strauss, William D. Tap, Fiona Thistlethwaite, Claudia Maria Valverde Morales, Michael J. Wagner, Breelyn A. Wilky, Cheryl McAlpine, Laura Hudson, Jean‐Marc Navenot, Tianjiao Wang, Jane P. F. Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian Andrew Van Tine - The Lancet 2024 cited by 263

  3. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

    Authors: Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, James N. Atkins, Mohammed Milhem, Balkrishna Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher - The Lancet Oncology 2018 cited by 748

  4. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis

    Authors: Jana Biermann, Johannes C. Melms, Amit Dipak Amin, Yiping Wang, Lindsay Caprio, Alcida Karz, Somnath Tagore, Irving Barrera, Miguel A. Ibarra-Arellano, Massimo Andreatta, Benjamin T. Fullerton, Kristjan H. Gretarsson, Varun Sahu, Vaibhav S. Mangipudy, Trang Nguyen, Ajay Nair, Meri Rogava, Patricia Ho, Peter D. Koch, Matei A. Banu, Nelson Humala, Aayushi Mahajan, Zachary Walsh, Shivem B. Shah, Daniel H. Vaccaro, Blake Caldwell, Michael Mu, Florian Wünnemann, Margot Chazotte, Simon Berhe, Adrienne Luoma, Joseph Driver, Matthew Ingham, Shaheer Khan, Suthee Rapisuwon, Craig L. Slingluff, Thomas Eigentler, Martin Röcken, Richard D. Carvajal, Michael B. Atkins, Michael A. Davies, Albert S. Agustinus, Samuel F. Bakhoum, Elham Azizi, Markus D. Siegelin, Chao Lü, Santiago J. Carmona, Hanina Hibshoosh, Antoni Ribas, Peter Canoll, Jeffrey N. Bruce, Wenya Linda Bi, Praveen Agrawal, Denis Schapiro, Eva Hernando, Evan Z. Macosko, Fei Chen, Gary K. Schwartz, Benjamin Izar - Cell 2022 cited by 219

  5. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Authors: Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Andrés Cervantes, Gary K. Schwartz, Glen J. Weiss, Luis Paz‐Ares, Daniel C. Cho, Jeffrey R. Infante, María Alsina, Mrinal M. Gounder, Rick Falzone, Jamie Harrop, Amy C. Seila White, Iva Toudjarska, David Bumcrot, Rachel Meyers, Gregory Hinkle, Nenad Svrzikapa, Renta Hutabarat, Valerie A. Clausen, Jeffrey Cehelsky, Saraswathy V. Nochur, Christina Gamba‐Vitalo, Akshay Vaishnaw, Dinah W.Y. Sah, Jared Gollob, Howard A. Burris - Cancer Discovery 2013 cited by 699

  6. Atezolizumab for Advanced Alveolar Soft Part Sarcoma

    Authors: Alice P. Chen, Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu, Brian A. Van Tine, Anthony P. Conley, William L. Read, Richard F. Riedel, Melissa Burgess, John Glod, Elizabeth J. Davis, Priscilla Merriam, Abdul Rafeh Naqash, Kristin Fino, Brandon Miller, Deborah Wilsker, Asma Begum, Katherine V. Ferry‐Galow, Hari A. Deshpande, Gary K. Schwartz, Brian H. Ladle, Scott H. Okuno, Jill C. Beck, James L. Chen, Naoko Takebe, Laura K. Fogli, Christina L. Rosenberger, Ralph E. Parchment, James H. Doroshow - New England Journal of Medicine 2023 cited by 152

  7. Sorafenib for Advanced and Refractory Desmoid Tumors

    Authors: Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, Mohammed Milhem, Robert M. Conry, Sujana Movva, Michael J. Pishvaian, Richard F. Riedel, Tarek Sabagh, William D. Tap, Natally Horvat, Ethan Basch, Lawrence H. Schwartz, Robert G. Maki, Narasimhan P. Agaram, Robert A. Lefkowitz, Yousef Mazaheri, Rikiya Yamashita, John J. Wright, Amylou C. Dueck, Gary K. Schwartz - New England Journal of Medicine 2018 cited by 449

  8. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

    Authors: Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida, Alexander Drilon, Ping Chi, Sandra P. D’ Angelo, Mark A. Dickson, Mary Lou Keohan, Ciara M. Kelly, Mark Agulnik, Sant P. Chawla, Edwin Choy, Rashmi Chugh, Christian F. Meyer, Parvathi A. Myer, Jessica L. Moore, Ross A. Okimoto, Raphael E. Pollock, Vinod Ravi, Arun S. Singh, Neeta Somaiah, Andrew J. Wagner, John H. Healey, Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin - Nature Communications 2022 cited by 193

  9. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

    Authors: Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Neil H Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloé Delépine, Tyler J. Curiel, Justin Stebbing, Heinz‐Josef Lenz, Steven O’Day, Anthony B. El-Khoueiry - Nature Medicine 2024 cited by 110

  10. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

    Authors: Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz, Amy Weise, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G. Tirunagaru, Feng Xu, Robert C. Doebele, David S. Hong - Journal of Clinical Oncology 2023 cited by 91

  11. Targeting the Cell Cycle: A New Approach to Cancer Therapy

    Authors: Gary K. Schwartz, Manish A. Shah - Journal of Clinical Oncology 2005 cited by 824

  12. Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens

    Authors: Yiping Wang, Joy Linyue Fan, Johannes C. Melms, Amit Dipak Amin, Yohanna Georgis, Irving Barrera, Patricia Ho, Somnath Tagore, Gabriel Abril-Rodríguez, Siyu He, Yinuo Jin, Jana Biermann, Matan Hofree, Lindsay Caprio, Simon Berhe, Shaheer Khan, Brian S. Henick, Antoni Ribas, Evan Z. Macosko, Fei Chen, Alison M. Taylor, Gary K. Schwartz, Richard D. Carvajal, Elham Azizi, Benjamin Izar - Nature Genetics 2023 cited by 59

  13. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

    Authors: Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn, Paul B. Chapman, Stephen Jay Frank, Anthony M. Joshua, Josep M. Piulats, Pascal Wolter, Véronique Cocquyt, Bartosz Chmielowski, T.R. Jeffry Evans, Lauris Gastaud, Gerald P. Linette, Carola Berking, Jacob Schachter, Manuel Rodrigues, Alexander N. Shoushtari, Delyth Clemett, Dana Ghiorghiu, G Mariani, Shirley Spratt, Susan Lovick, Peter Barker, Elaine Kilgour, Zhongwu Lai, Gary K. Schwartz, Paul Nathan - Journal of Clinical Oncology 2018 cited by 275

  14. Cell-Cycle Therapeutics Come of Age

    Authors: Matthew Ingham, Gary K. Schwartz - Journal of Clinical Oncology 2017 cited by 395

  15. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib

    Authors: Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan, Sandra P. D’Angelo, Mrinal M. Gounder, Ping Chi, Cristina R. Antonescu, Jonathan Landa, Li‐Xuan Qin, Aimeé M. Crago, Samuel Singer, Andrew Koff, William D. Tap - JAMA Oncology 2016 cited by 324

  16. Metastatic disease from uveal melanoma: treatment options and future prospects

    Authors: Richard D. Carvajal, Gary K. Schwartz, Tongalp H. Tezel, Brian P. Marr, Jasmine H. Francis, Paul Nathan - British Journal of Ophthalmology 2016 cited by 443

  17. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Authors: Jyoti D. Patel, Lada Krilov, Sylvia Adams, Carol Aghajanian, Ethan Basch, Marcia S. Brose, William L. Carroll, Marcos de Lima, Mark R. Gilbert, Mark G. Kris, John L. Marshall, Gregory A. Masters, Steven O’Day, Blasé N. Polite, Gary K. Schwartz, Sunil Sharma, Ian M. Thompson, Nicholas J. Vogelzang, Bruce J. Roth - Journal of Clinical Oncology 2013 cited by 435

  18. Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Authors: Ethan Basch, Claus Becker, Lauren J. Rogak, Deborah Schrag, Bryce B. Reeve, Patricia A. Spears, Mary Lou Smith, Mrinal M. Gounder, Michelle R. Mahoney, Gary K. Schwartz, Antonia V. Bennett, Tito R. Mendoza, Charles S. Cleeland, Jeff A. Sloan, Deborah Watkins Bruner, Gisela Schwab, Thomas M. Atkinson, Gita Thanarajasingam, Monica M. Bertagnolli, Amylou C. Dueck - Clinical Trials 2020 cited by 246

  19. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

    Authors: Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton, P. Mickey Williams, Edith P. Mitchell, A. John Iafrate, Jeffrey Sklar, Lyndsay N. Harris, Lisa M. McShane, Larry Rubinstein, David Sims, Mark Routbort, Brent Coffey, Tony Fu, James A. Zwiebel, Richard F. Little, Donna M. Marinucci, Robert B. Catalano, Rick Magnan, Warren A. Kibbe, Carol J. Weil, James V. Tricoli, Brian M. Alexander, Shaji Kumar, Gary K. Schwartz, Funda Meric‐Bernstam, Chih‐Jian Lih, Worta McCaskill‐Stevens, Paolo F. Caimi, Naoko Takebe, Vivekananda Datta, Carlos L. Arteaga, Jeffrey S. Abrams, Robert L. Comis, Peter J O’Dwyer, Barbara A. Conley, for the NCI-MATCH Team - JNCI Journal of the National Cancer Institute 2020 cited by 228

  20. Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

    Authors: Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo, Mohammed Milhem, Anthony M. Joshua, Ragini R. Kudchadkar, Gerald P. Linette, Thomas F. Gajewski, Jose Lutzky, David H. Lawson, Christopher D. Lao, Patrick J. Flynn, Mark R. Albertini, Takami Sato, Karl D. Lewis, Austin Doyle, Kristin Kathleen Ancell, Katherine S. Panageas, Mark J. Bluth, Cyrus V. Hedvat, Joseph P. Erinjeri, Grazia Ambrosini, Brian P. Marr, David H. Abramson, Mark A. Dickson, Jedd D. Wolchok, Paul B. Chapman, Gary K. Schwartz - JAMA 2014 cited by 429

  21. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

    Authors: Patricia Ho, Johannes C. Melms, Meri Rogava, Chris J. Frangieh, Joanna Poźniak, Shivem B. Shah, Zachary Walsh, Oleksandr Kyrysyuk, Amit Dipak Amin, Lindsay Caprio, Benjamin T. Fullerton, Rajesh K. Soni, Casey R. Ager, Jana Biermann, Yi‐Ping Wang, Mohsen Khosravi‐Maharlooei, Giorgia Zanetti, Michael Mu, Hijab Fatima, Emily K. Moore, Neil Vasan, Samuel F. Bakhoum, Steven L. Reiner, Chantale Bernatchez, Megan Sykes, Emily M. Mace, Kai W. Wucherpfennig, Dirk Schadendorf, Oliver Bechter, Parin Shah, Gary K. Schwartz, Jean‐Christophe Marine, Benjamin Izar - Cancer Cell 2023 cited by 94

  22. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

    Authors: Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon, Apostolia M. Tsimberidou, Andrea J. Bullock, Breelyn A. Wilky, Jonathan C. Trent, Kim Margolin, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Bruno Bockorny, Justin C. Moser, Joseph E. Grossman, W.I. Ortuzar Feliu, Katherine Rosenthal, Steven O’Day, Heinz‐Josef Lenz, Benjamin L. Schlechter - Journal of Clinical Oncology 2023 cited by 55

  23. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

    Authors: Jordi Barretina, Barry S. Taylor, Shantanu Banerji, Alexis Ramos, Mariana Lagos‐Quintana, Penelope DeCarolis, Kinjal Shah, Nicholas D. Socci, Barbara A. Weir, Alan L. Ho, Derek Y. Chiang, Boris Reva, Craig H. Mermel, Gad Getz, Yevgenyi Antipin, Rameen Beroukhim, John E. Major, Charles Hatton, Richard Nicoletti, Megan Hanna, Ted Sharpe, Tim Fennell, Kristian Cibulskis, Robert C. Onofrio, Tsuyoshi Saito, Neerav Shukla, Christopher Lau, Sven Nelander, Serena J. Silver, Carrie Sougnez, Agnès Viale, Wendy Winckler, Robert G. Maki, Levi A. Garraway, Alex Lash, Heidi Greulich, David E. Root, William R. Sellers, Gary K. Schwartz, Cristina R. Antonescu, Eric S. Lander, Harold Varmus, Marc Ladanyi, Chris Sander, Matthew Meyerson, Samuel Singer - Nature Genetics 2010 cited by 726

  24. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer

    Authors: Sung Soo Kim, Jessica Armand, Anton Safonov, Mimi Zhang, Rajesh K. Soni, Gary K. Schwartz, Julia E. McGuinness, Hanina Hibshoosh, Pedram Razavi, Minah Kim, Sarat Chandarlapaty, Hee Won Yang - Cell Reports 2023 cited by 56